Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of metabolic diseases. Headquartered in San Diego, California, the company targets innate homeostatic pathways to address hunger-associated conditions. Its lead candidate, ARD-101, is an oral drug designed to treat hyperphagia associated with rare diseases such as Prader-Willi Syndrome.
Aardvark is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for commercial sale and has not generated any product revenue to date; accordingly, it has no commercial customers or customer concentration.